Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)
Australian Clinical Labs Ltd Business Overview & Revenue Model
Australian Clinical Labs Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 741.27M | 741.27M | 689.73M | 692.10M | 989.30M | 641.31M |
| Gross Profit | 270.86M | 270.86M | 138.45M | 566.02M | 781.71M | 521.73M |
| EBITDA | 81.36M | 81.36M | 169.65M | 184.93M | 372.75M | 196.67M |
| Net Income | 32.43M | 32.43M | 23.93M | 35.90M | 178.24M | 60.37M |
Balance Sheet | ||||||
| Total Assets | 574.84M | 574.84M | 593.06M | 578.91M | 628.04M | 474.70M |
| Cash, Cash Equivalents and Short-Term Investments | 22.12M | 22.12M | 26.84M | 20.59M | 27.51M | 36.28M |
| Total Debt | 290.38M | 290.38M | 308.90M | 316.32M | 262.38M | 294.26M |
| Total Liabilities | 402.86M | 402.86M | 415.30M | 406.24M | 395.49M | 392.79M |
| Stockholders Equity | 171.35M | 171.35M | 177.53M | 172.42M | 232.44M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 174.39M | 174.39M | 153.09M | 136.75M | 262.83M | 144.36M |
| Operating Cash Flow | 182.80M | 182.80M | 159.59M | 143.68M | 284.09M | 153.86M |
| Investing Cash Flow | -8.89M | -8.89M | -7.25M | -12.18M | -72.04M | -6.08M |
| Financing Cash Flow | -178.74M | -178.74M | -146.14M | -137.88M | -220.91M | -147.37M |
Australian Clinical Labs Ltd Technical Analysis
Australian Clinical Labs Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$520.92M | 15.80 | 18.59% | 4.60% | 6.73% | 37.16% | |
64 Neutral | AU$11.07B | 20.94 | 6.32% | 4.69% | 9.44% | -0.37% | |
55 Neutral | AU$947.23M | 167.11 | 0.94% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$707.98M | -1.35 | -67.21% | ― | -23.02% | 33.11% |
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Limited has cancelled 200,000 fully paid ordinary shares as part of an on‑market share buy-back, effective 22 December 2025. The reduction in issued capital reflects the company’s ongoing capital management strategy, which may incrementally enhance earnings per share and signal management’s confidence in the business to investors.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has cancelled 849,070 fully paid ordinary shares following an on‑market buy-back completed on 19 December 2025. The reduction in issued capital through this buy-back is likely to enhance capital management efficiency and may be marginally accretive to remaining shareholders, reflecting the company’s active approach to optimising its balance sheet and shareholder structure.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has provided an updated notification to the ASX on its on‑market share buy-back, confirming that it is repurchasing ordinary fully paid shares under an existing buy-back program first notified in October 2025. As of 19 December 2025, the company reports a cumulative 3,370,516 shares bought back prior to the previous trading day and a further 200,000 shares repurchased on the previous day, indicating continued execution of its capital management strategy and a likely focus on enhancing shareholder value and optimising its balance sheet through reducing the number of shares on issue.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has released a notification regarding its ongoing on-market share buy-back program, stating that a total of 300,000 ordinary shares were repurchased on the previous day. This initiative highlights the company’s effort to optimize its capital structure, potentially improving shareholder value and reaffirming confidence in its financial position.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of December 17, 2025, the company has repurchased a total of 3,070,516 securities, including 117,599 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program. As of December 16, 2025, the company has repurchased a total of 2,768,487 ordinary fully paid securities, with an additional 184,430 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the issuance of unquoted equity securities, including 110,528 service rights and 663,168 performance rights, under an employee incentive scheme. This move is likely aimed at enhancing employee engagement and aligning staff interests with company goals, potentially impacting the company’s operational dynamics and stakeholder relations.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the cessation of 38,121 service rights due to unmet conditions, impacting its issued capital. This development may influence the company’s financial structure and could have implications for stakeholders regarding the company’s operational and strategic adjustments.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 15, 2025, the company has repurchased a total of 2,768,487 ordinary fully paid securities, including 136,041 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. As of December 12, 2025, the company has repurchased a total of 2,632,446 ordinary fully paid securities, with 111,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 11, 2025, the company has bought back a total of 2,521,446 ordinary fully paid securities, including 250,000 on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities, with a total of 2,161,740 securities bought back before the previous day and an additional 109,706 securities bought back on the previous day. This buy-back initiative reflects the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program, with a total of 101,866 ordinary fully paid securities bought back on the previous day, bringing the total to 2,059,874 securities. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the cessation of 701,165 ordinary fully paid securities due to an on-market buy-back, effective December 5, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and market perception by reducing the number of outstanding shares.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 8, 2025, the company has repurchased a total of 2,059,874 ordinary fully paid securities, including 127,390 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 4, 2025, the company has repurchased a total of 1,932,484 ordinary fully paid securities, including 150,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update on its ongoing share buy-back program, revealing that a total of 289,740 ordinary fully paid securities were bought back on the previous day, bringing the total number of securities bought back to 1,492,744. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, potentially impacting its market positioning and investor relations positively.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 2, 2025, the company has repurchased a total of 1,492,744 ordinary fully paid securities, including 175,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced an update regarding its ongoing share buy-back program. As of November 27, 2025, the company has repurchased a total of 1,231,319 shares, with 27,843 shares bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced an update on its ongoing share buy-back program, revealing that a total of 1,006,789 securities had been bought back before the previous day, with an additional 196,687 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the cessation of 550,000 fully paid ordinary securities as part of an on-market buy-back, effective November 19, 2025. This move is likely aimed at optimizing the company’s capital structure and could have implications for shareholder value and market perception.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the issuance and conversion of unquoted equity securities, with a total of 83,853 ordinary fully paid securities being issued on specified dates in 2023. This move could impact the company’s financial structure and shareholder value, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of November 18, 2025, the company has repurchased a total of 549,627 ordinary fully paid securities, with an additional 200,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of November 14, 2025, the company has repurchased a total of 399,627 ordinary fully paid securities, with 200,000 bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has announced an update regarding their on-market buy-back of ordinary fully paid securities, with a total of 199,627 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure, potentially enhancing shareholder value and signaling confidence in its financial health.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced the issuance and conversion of unquoted equity securities, with a total of 187,668 ordinary fully paid securities being issued. This move may impact the company’s financial structure and could have implications for its market positioning and shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced a change in the director’s interest in securities. Stephen Roche, a director, has acquired 70,000 ordinary shares at $2.77 per share, marking his direct interest in the company through the Steann Superannuation Fund. This transaction, conducted on-market, indicates a significant personal investment by the director, potentially reflecting confidence in the company’s future performance.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.85 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd has announced the final notification of its buy-back program, where a total of 6,042,629 ordinary fully paid securities were bought back for a total consideration of AUD 19,101,121.57. This buy-back is part of the company’s strategic financial management, potentially impacting its market positioning by reducing the number of outstanding shares, which may enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Ltd announced the results of its 2025 Annual General Meeting, where several key resolutions were passed, including the re-election of directors Sarah Butler, Grant Jeffery, Stephen Roche, and Mark Haberlin, as well as the adoption of the 2025 Remuneration Report. The spill resolution was not carried. These outcomes reflect the company’s stable governance structure and commitment to maintaining its leadership team, which may reassure stakeholders about the company’s strategic direction and operational continuity.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the withdrawal of Resolution 5 from its Annual General Meeting agenda following the resignation of Dr. Leanne Rowe AM. The meeting will proceed as planned on 23 October 2025. This change reflects an adjustment in the company’s governance structure, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited announced the resignation of Dr. Leanne Rowe AM from its Board, effective immediately, due to personal reasons. Dr. Rowe, who joined the Board during the company’s IPO in April 2021, brought significant medical and leadership expertise, contributing greatly to the Board’s skill set and supporting the senior executive team. Her departure is noted as a loss for the company, which expressed gratitude for her contributions and wished her well in future endeavors.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited (ACL) has reached a resolution with the Australian Information Commissioner regarding a civil penalty proceeding related to a cyberattack on its Medlab Pathology business. The Federal Court of Australia has approved an agreement requiring ACL to pay $5.8 million in civil penalties and contribute $400,000 towards legal costs, concluding the proceedings and potentially impacting ACL’s financial standing and stakeholder relations.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
Australian Clinical Labs Limited has reached an agreement with the Australian Information Commissioner to resolve a civil penalty proceeding related to a cyberattack on Medlab Pathology, which occurred shortly after ACL acquired the business. The agreement includes a proposed penalty of $5.8 million and a contribution of $400,000 towards legal costs, pending Federal Court approval. The cyberattack did not affect ACL’s systems, and the company has since integrated Medlab’s IT systems into its own robust cybersecurity framework. This resolution allows ACL to focus on its strategic goals and continue delivering high-quality pathology services.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.